Custom Bioconjugation Service

Bioconjugation creates essential reagents for immunogens, vaccines, and diagnostics. Creative Biolabs is a leading biology CRO who has decades of experience in conjugate vaccines. Scientists of Creative Biolabs are experts in the design and synthesis of conjugate vaccines and help our customers with "off the shelf" bioconjugation products using our advanced bioconjugation processes.

Bioconjugation Technology for Vaccines

Creative Biolabs has developed a new strategy for the preparation of vaccine candidates using a bioconjugation method. The ability to create technically challenging yet safe and efficacious bioconjugation-based drug through bioconjugation process has affected every discipline of life science. With our state-of-the-art manufacturing facility and over 10 years of experience in bioconjugate technologies, we have delivered thousands of hybrid complexes. With the development of new cross-linking technologies and reagents, new applications for vaccine development are being advanced through the development of novel bioconjugates. The development of bioconjugation technology is attributed to the discovery of chemoselective reactions that are capable of bioconjugation under physiological conditions. Creative Biolabs has all the expertise and resources to do this kind of project, from molecular design to manufacturing, from small molecule synthesis to big molecule modification and conjugation, purification, and testing.

Bioconjugation Process inBacterial Cells

Bacterial polysaccharides conjugated to proteins have been developed as vaccines and used effectively over the past two decades. Many different bacterial surface polysaccharides, such as capsular polysaccharides and lipopolysaccharides, are important virulence factors and are targets for vaccine development. The increasing evidence that prokaryotes can glycosylate proteins has put an end to the doctrine that restricted glycoproteins to eukaryotes. Creative Biolabs provides the biotechnology that an antigenic polysaccharide is attached to a selected protein carrier by enzymatic conjugation and produces a conjugated antigen in the bacterial cell, such as E. coli. Many bacteria, including several human pathogens, contain glycoproteins in their surface appendages such as flagella and pili. This procedure is expected to be advantageous because glycoproteins could be purified in a few steps from E. coli fermentations, without the need for culturing pathogenic or slow-growing bacteria. Because no chemical treatments such as removal of endotoxin and crosslinking are necessary and the length of the O polysaccharide is controlled in vivo, the conjugates contain a defined and reproducible sugar pattern.

Fig.1 Process of in vivo bioconjugation, using recombinant Escherichia coli. (Poolman JT. 2016)

Features of Our Services

• Glycoproteins could be purified in a few steps from E. coli fermentations.
• No need for culturing pathogenic or slow-growing bacteria.
• Provide potential solutions to many problems involved in the chemical conjugation process.
• No chemical treatments such as removal of endotoxin and crosslinking.
• The length of the polysaccharide can be controlled in vivo, thus the conjugates contain a defined and reproducible sugar pattern.
• The bioconjugation process does not need chemical materials and is thereby expected to maintain its native conformational antigenic structure.
• Suitable for large-scale production of conjugates which cannot be produced with traditional chemical conjugation technology.
• Homogeneous and well-defined products.
• High batch-to-batch consistency.
• Shorter development time lines at lower costs.

In our custom conjugation service for vaccines, clients specify the kinds of molecules are to be conjugated and we will design and produce the molecule using our bioconjugation process to make the conjugate and provide it to the customer. Creative Biolabs provides project management oversight through weekly conference calls and meeting minutes to track the progress of projects, action items, and timelines. We strive with competence and confidence to meet your demand for creating novel conjugates and to promote vaccine development.

Reference

1. Poolman JT. (2016). "Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field." J Infect Dis. 213(1):6-13.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.